The firm's financial position is increasingly precarious, with total assets declining from $7.0 million in 2025Q2 to $5.0 million by 2026Q1, reflecting ongoing capital depletion.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Oct'13 | Oct'12 | Oct'09 |
|---|
| Total Current Assets | 4.98M | 5.8M | 3.86M | 3.74M | 8.5M | 6.68M | 0 | 30.83K | 1.04M | 795.51K | 700.9K | 1.54M | 3.81M | 87.31K | 0 | -39.77K |
| Cash & Short-Term Investments | 4.53M | 5.33M | 3.33M | 3.03M | 7.54M | 6.68M | 0 | 24.14K | 955.37K | 690.28K | 620.38K | 1.12M | 2.66M | 1.54K | 0 | -39.77K |
| Cash Only | 4.53M | 5.33M | 3.33M | 3.03M | 7.54M | 6.68M | 0 | 24.14K | 955.37K | 690.28K | 620.38K | 1.12M | 2.66M | 1.54K | 0 | -39.77K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 7.81K | 9.89K | 0 | 328.84K | 579.91K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.06M | 75K | 0 | 0 |
| Total Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 146 | 242 | 5.8K | 11.62K | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 146 | 242 | 5.8K | 11.62K | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 4.98M | 5.8M | 3.86M | 3.74M | 8.5M | 6.68M | 0 | 30.83K | 1.04M | 795.66K | 973.09K | 2.08M | 3.82M | 87.31K | 0 | -39.77K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 283.04% | 50.11% | 3.31% | -56% | 27.26% | - | -100% | -97.04% | 30.8% | -18.23% | -53.22% | -45.56% | 4277.06% | - | 100% | - |
| Total Current Liabilities | 309.39K | 418.59K | 377.71K | 831.4K | 2.55M | 99.91K | 13.69M | 578.45K | 9.64M | 961.79K | 1.5M | 2.15M | 3.87M | 5.7M | 4.68K | 0 |
| Accounts Payable | 308.95K | 417.88K | 373.04K | 360.66K | 104.79K | 99.91K | 465.4K | 42.88K | 125.2K | 216.9K | 226.52K | 186.81K | 119.78K | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - | 313.02K | 476.03K | 824.68K | 118.11K | 15.32K | 49.81 | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 11.72M | 0 | 9M | 0 | 1.2M | 0 | 3.66M | 4.13M | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 783.67K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 438 | 703 | 4.67K | 470.74K | 1.66M | 0 | 0 | 253.55K | 0 | 456K | 22.38K | 1.82M | 0 | 201.71K | 4.68K | 0 |
| Current Ratio | 16.09x | 13.85x | 10.22x | 4.50x | 3.33x | 66.81x | - | 0.05x | 0.11x | 0.83x | 0.47x | 0.72x | 0.98x | 0.02x | - | - |
| Quick Ratio | 16.09x | 13.85x | 10.22x | 4.50x | 3.33x | 66.81x | - | 0.05x | 0.11x | 0.83x | 0.47x | 0.72x | 0.98x | 0.02x | - | - |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.32M | 0 | 8.23M | 7.56M | 5.08M | 3.65M | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.32M | 0 | 8.23M | 7.56M | 5.08M | 3.65M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 309.39K | 418.59K | 377.71K | 831.4K | 2.55M | 99.91K | 13.69M | 11.9M | 9.64M | 9.19M | 9.61M | 7.76M | 7.52M | 5.7M | 4.68K | 0 |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 11.72M | 11.32M | 9M | 8.23M | 8.76M | 5.08M | 7.3M | 4.13M | 0 | 0 |
| Net Debt | -4.53M | -5.33M | -3.33M | -3.03M | -7.54M | -6.68M | 11.72M | 11.3M | 8.04M | 7.54M | 6.86M | 4.5M | 4.64M | 4.13M | 0 | 39.77K |
| Debt / Equity | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.51x | - | -20652.99x | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -1.03x | -1.00x | -0.83x | -2.51x | -2.27x | -0.59x | -8.89x | -6.41x | -2.15x | - | - | - |
| Total Equity | 4.67M | 5.38M | 3.48M | 2.91M | 5.95M | 6.58M | -13.69M | -11.87M | -8.6M | -8.4M | -8.63M | -5.68M | -3.7M | -5.61M | -4.68K | 0 |
| Equity Growth % | 300.19% | 54.36% | 19.86% | -51.13% | -9.55% | 148.02% | -15.38% | -38.02% | -2.41% | 2.76% | -51.98% | -53.6% | 34.05% | -119833.83% | - | - |
| Book Value per Share | 2.60 | 4.58 | 2.30 | 11.05 | 124.79 | 152.47 | -267.75 | -232.07 | -6159.15 | -7766.72 | -8262.25 | -7185.57 | -8904.82 | -1.12 | -0.00 | - |
| Total Shareholders' Equity | 4.67M | 5.38M | 3.48M | 2.91M | 5.95M | 6.58M | -13.69M | -11.87M | -8.6M | -8.4M | -8.36M | -5.68M | -3.7M | -5.61M | -4.68K | 0 |
| Common Stock | 1.79K | 1.79K | 2.95K | 534 | 15.3K | 10.35K | 30.68K | 30.68K | 26.45K | 43.28K | 38.83K | 32.21K | 24.27K | 10.93K | 11 | 0 |
| Retained Earnings | -88.9M | -88.13M | -85.02M | -80.91M | -71.96M | -70.48M | -68.86M | -67.04M | -63.62M | -59.19M | -52.13M | -25.91M | -12.04M | -7.61M | -6.53K | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -357 | 1.82M | -3.98K | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Binary clinical trial failure
As reported in recent financial statements, BBLG's total assets have declined from $7.0 million in 2025Q2 to $5.0 million by 2026Q1, reflecting a consistent trend of capital depletion as the firm funds its pre-commercial clinical development without any offsetting revenue streams to replenish its balance sheet.
The downward trajectory of total assets highlights the company's reliance on cash reserves to sustain operations. This trend suggests that the firm's survival is tethered to its ability to secure external funding before its current liquidity buffer is exhausted.
Based on the latest quarterly data, BBLG maintains a cash position of $4.5 million as of 2026Q1, which represents a significant reduction from the $6.6 million reported in 2025Q2, indicating a tightening liquidity window that warrants close monitoring by investors concerned with potential near-term insolvency risks.
While the current ratio remains high due to the lack of significant liabilities, this metric is misleading as it masks the underlying reality of a company with no revenue. The rapid consumption of cash suggests that the firm may face increasing pressure to execute dilutive financing events to maintain its clinical trial momentum.
According to historical balance sheet data, BBLG's retained earnings have reached a deficit of $88.9 million as of 2026Q1, a figure that underscores the substantial value destruction inherent in the company's long-term pursuit of regulatory approval for its NELL-1 protein technology without achieving commercial viability.
The persistent growth of the accumulated deficit reflects the high cost of clinical development and the absence of operational income. This trend suggests that existing shareholders face significant dilution risk as the company continues to rely on equity issuance to bridge the gap between its current state and potential commercialization.
As indicated by the provided financial data, the company's balance sheet is essentially a shell for its intellectual property, with zero PPE and zero goodwill, meaning that the firm's entire enterprise value is contingent upon the success of its singular clinical trial pathway for NELL-1.
Investors should note that the absence of tangible assets or revenue-generating infrastructure makes the balance sheet highly sensitive to binary clinical outcomes. Any failure in the L4-S1 trial would likely render the current asset base effectively worthless, as there are no secondary assets to provide a floor for valuation.
Quick answers to the most common questions about buying BBLG stock.
As of 2025, Bone Biologics Corporation (BBLG) had total assets of $5.8M including $5.8M in current assets.
Bone Biologics Corporation (BBLG) carries total debt of $0.0M, offset by $5.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Bone Biologics Corporation (BBLG) has total shareholders' equity (book value) of $5.4M ($4.58 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Bone Biologics Corporation (BBLG) reported a current ratio of 13.85x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.